Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Was macht Atara Biotherapeutics?
Unternehmensprofil
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Chart der Atara Biotherapeutics Aktie
Charttool öffnen
Aktuelle Nachrichten zu Atara Biotherapeutics
Weitere Nachrichten
Das berichten andere über Atara Biotherapeutics
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 68.85% and 150.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to...
Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet
The consensus price target hints at a 33% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective,...
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
Wir finden für unsere Leser softwaregestützt die besten Aktien der Welt
und schreiben darüber, wie man diese handeln muss, um Geld zu verdienen.